- Home
- RCMT vs DRUG Comparison
RCMT vs DRUG Comparison
Compare RCMT & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCMT
- DRUG
- Stock Information
- Founded
- RCMT 1971
- DRUG 2019
- Country
- RCMT United States
- DRUG United States
- Employees
- RCMT N/A
- DRUG N/A
- Industry
- RCMT Professional Services
- DRUG Pharmaceuticals and Biotechnology
- Sector
- RCMT Consumer Discretionary
- DRUG Health Care
- Exchange
- RCMT Nasdaq
- DRUG Nasdaq
- Market Cap
- RCMT 172.2M
- DRUG 199.7M
- IPO Year
- RCMT N/A
- DRUG N/A
- Fundamental
- Price
- RCMT $23.49
- DRUG $33.63
- Analyst Decision
- RCMT Strong Buy
- DRUG Strong Buy
- Analyst Count
- RCMT 2
- DRUG 7
- Target Price
- RCMT $33.50
- DRUG $83.25
- AVG Volume (30 Days)
- RCMT 52.1K
- DRUG 37.4K
- Earning Date
- RCMT 08-06-2025
- DRUG 08-13-2025
- Dividend Yield
- RCMT N/A
- DRUG N/A
- EPS Growth
- RCMT N/A
- DRUG N/A
- EPS
- RCMT 1.74
- DRUG N/A
- Revenue
- RCMT $290,914,000.00
- DRUG N/A
- Revenue This Year
- RCMT $16.29
- DRUG N/A
- Revenue Next Year
- RCMT $6.16
- DRUG N/A
- P/E Ratio
- RCMT $13.53
- DRUG N/A
- Revenue Growth
- RCMT 8.53
- DRUG N/A
- 52 Week Low
- RCMT $13.18
- DRUG $0.94
- 52 Week High
- RCMT $27.24
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- RCMT 39.96
- DRUG 64.40
- Support Level
- RCMT $24.63
- DRUG $31.80
- Resistance Level
- RCMT $26.11
- DRUG $36.50
- Average True Range (ATR)
- RCMT 0.85
- DRUG 2.44
- MACD
- RCMT -0.30
- DRUG 0.79
- Stochastic Oscillator
- RCMT 12.89
- DRUG 70.86
About RCMT RCM Technologies Inc.
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.